Literature DB >> 30535934

Overall Survival of Primary Intracranial Atypical Teratoid Rhabdoid Tumor Following Multimodal Treatment: A Pooled Analysis of Individual Patient Data.

Xiu-Jian Ma1, Da Li2, Liang Wang1, Shu-Yu Hao1, Li-Wei Zhang1, Jun-Ting Zhang1, Zhen Wu3.   

Abstract

No standard treatment protocol to guide the management of the primary central nervous system atypical teratoid rhabdoid tumors (ATRTs). To evaluate the efficacy of GTR (gross total resection), RT (radiotherapy), CCMT (conventional chemotherapy), or intensified chemotherapy (ICMT) and verify the optimal treatment strategy. A total of 501 cases (18 cases from our center and 483 cases from published literature) were eligible for analysis. Clinical characteristics were reviewed, and overall survival (OS) of each combined treatment modality was compared. These prior publication data were processed according to PRISMA guidelines. This study included 265 (52.9%) males and 216 (43.1%) females. The median age of the cohort was 2.2 years with 295 (58.9%) cases younger than 3 years. GTR was achieved in 217 (43.3%) patients. Initial adjuvant CCMT, CCMT plus intrathecal chemotherapy (ITCMT), CCMT plus high-dose chemotherapy (HDCMT), and CCMT plus ITCMT and HDCMT were administered in 228 (45.5%), 78 (15.6%), 55 (11.0%), and 24 (4.8%) patients, respectively. Radiotherapy (RT) was prescribed in 266 (53.1%) patients. Fewer patients younger than 3 years old received RT (21.9% vs 33.0%, p < 0.001, chi-square test). The OS of the entire cohort at 1, 3, and 5 years were 56.6, 35.9, and 30.8%, respectively. After adjusting for age and sex, GTR (HR 0.630; p < 0.001), RT (HR = 0.295; p < 0.001), CCMT (HR = 0.382; p < 0.001), and ICMT (HR = 0.209; p < 0.001) were independent prognostic factors. The 3-year OS of surgery alone, surgery plus CCMT, surgery plus RT, surgery plus ICMT, surgery plus CCMT and RT, and surgery plus ICMT and RT were 8.9, 13.4, 23.7, 37.4, 48.3, and 68.5%, respectively. When taking into consideration the extent of tumor resection (n = 462), GTR followed by RT, CCMT, intrathecal chemotherapy, and high-dose chemotherapy provided the best OS (5-year OS 88.2%). In younger children, adjuvant ICMT had a greater 3-year OS than adjuvant RT alone (34.0% vs 0%, p = .001). This study identified independent favorable predictors for OS of ATRTs and distinguished significantly different OS following various treatment modalities. If tolerable, intensive treatment with GTR followed by adjuvant RT and ICMT is recommended. Intensified CCMT could be an alternative to avoid radiological radiotoxicity for younger children CRD42018098841.

Entities:  

Keywords:  Atypical teratoid rhabdoid tumors; Central nervous system; Chemotherapy; Multimodal treatment; Radiotherapy

Year:  2018        PMID: 30535934     DOI: 10.1007/s10143-018-1055-9

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  39 in total

1.  Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience).

Authors:  Yi-Wei Chen; Tai-Tong Wong; Donald Ming-Tak Ho; Pin-I Huang; Kai-Ping Chang; Cheng-Ying Shiau; Sang-Hue Yen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-06       Impact factor: 7.038

2.  Long-term cognitive sequelae after pediatric brain tumor related to medical risk factors, age, and sex.

Authors:  Ingrid Tonning Olsson; Sean Perrin; Johan Lundgren; Lars Hjorth; Aki Johanson
Journal:  Pediatr Neurol       Date:  2014-06-26       Impact factor: 3.372

3.  Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996-2006.

Authors:  Adelheid Woehrer; Irene Slavc; Thomas Waldhoer; Harald Heinzl; Nadine Zielonke; Thomas Czech; Martin Benesch; Johannes A Hainfellner; Christine Haberler
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

4.  Clinicopathological characteristics of atypical teratoid/rhabdoid tumor.

Authors:  H Oka; B W Scheithauer
Journal:  Neurol Med Chir (Tokyo)       Date:  1999-07       Impact factor: 1.742

5.  Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database.

Authors:  Benjamin W Fischer-Valuck; Ishita Chen; Amar J Srivastava; John M Floberg; Yuan James Rao; Allison A King; Eric T Shinohara; Stephanie M Perkins
Journal:  Cancer       Date:  2016-11-02       Impact factor: 6.860

6.  Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience.

Authors:  L Lafay-Cousin; C Hawkins; A S Carret; D Johnston; S Zelcer; B Wilson; N Jabado; K Scheinemann; D Eisenstat; C Fryer; A Fleming; C Mpofu; V Larouche; D Strother; E Bouffet; A Huang
Journal:  Eur J Cancer       Date:  2011-10-22       Impact factor: 9.162

7.  Central nervous system atypical teratoid rhabdoid tumor: experience at the National Institute of Pediatrics, Mexico City.

Authors:  Beatriz de León-Bojorge; Fernando Rueda-Franco; Marcial Anaya-Jara
Journal:  Childs Nerv Syst       Date:  2007-09-18       Impact factor: 1.475

8.  Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors.

Authors:  Karen De Amorim Bernstein; Roshan Sethi; Alexei Trofimov; Chuan Zeng; Barbara Fullerton; Beow Y Yeap; David Ebb; Nancy J Tarbell; Torunn I Yock; Shannon M MacDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-13       Impact factor: 7.038

9.  A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience.

Authors:  Paola Fidani; Maria Antonietta De Ioris; Annalisa Serra; Luigi De Sio; Ilaria Ilari; Raffaele Cozza; Renata Boldrini; Giuseppe Maria Milano; Maria Luisa Garrè; Alberto Donfrancesco
Journal:  J Neurooncol       Date:  2008-11-29       Impact factor: 4.130

10.  Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.

Authors:  Iyad Sultan; Ibrahim Qaddoumi; Carlos Rodríguez-Galindo; Anwar Al Nassan; Khalil Ghandour; Maysa Al-Hussaini
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

View more
  3 in total

1.  Long-Term Remission of a Spinal Atypical Teratoid Rhabdoid Tumor in Response to Intensive Multimodal Therapy.

Authors:  Fahd Refai; Haneen Al-Maghrabi; Hassan Al Trabolsi; Jaudah Al-Maghrabi
Journal:  Case Rep Pediatr       Date:  2019-10-13

2.  Adult Sellar Region Atypical Teratoid/Rhabdoid Tumor: A Retrospective Study and Literature Review.

Authors:  Fujun Liu; Shucai Fan; Xin Tang; Shuangmin Fan; Liangxue Zhou
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

3.  Atypical Teratoid/Rhabdoid Tumor in Taiwan: A Nationwide, Population-Based Study.

Authors:  Yen-Lin Liu; Min-Lan Tsai; Chang-I Chen; Noi Yar; Ching-Wen Tsai; Hsin-Lun Lee; Chia-Chun Kuo; Wan-Ling Ho; Kevin Li-Chun Hsieh; Sung-Hui Tseng; James S Miser; Chia-Yau Chang; Hsi Chang; Wen-Chang Huang; Tai-Tong Wong; Alexander T H Wu; Yu-Chun Yen
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.